Melatonin as an antioxidant: under promises but over delivers
April 18, 2026 Drugs Consultative Committee 68th meeting flags surrogate advertising of GLP-1 obesity drugs state regulators directed to enforce Medical Dialogues March 24, 2026 CDSCO tightens checks on generic semaglutide bans promotional activity, intensifies pharmacy surveillance Business Standard March 21, 2026 Patent expiry Day 1 8+ manufacturers launch simultaneously, prices fall up to 90% from branded versions CNBC March 17, 2026 ZydusLupin and ZydusTorrent licensing agreements announced ahead of patent expiry Pearce IP February 2026 Natco Pharma receives CDSCO approval for generic semaglutide Eris Lifesciences to commercialise Fierce Pharma December 2025 Sun Pharma receives first DCGI approval for generic semaglutide in India Noveltreat and Sematrinity Sun Pharma PR REGULATORY FRAMEWORK CDSCO Standards & Approval Requirements in India India's Central Drugs Standard Control Organisation (CDSCO) is the national drug regulator equivalent to the US FDA
Besides, the fibrosis score did not change significantly according to within- and between-group analyses
Educational resources In addition to the documents linked above, WADA has provided, or will provide, educational resources as part of its Code Implementation Support Program (CISP), which can be accessed on the Agencys Anti-Doping Education and Learning Platform (ADEL)
Cancer prevention is not a reason for a healthy-weight woman to start a GLP-1
Some patients might experience RWG and a recurrence of diabetes
